(112 days)
with PillCam™ SB Capsule: The Given® Diagnostic System with the PillCam™ SB Capsule is intended for visualization of the small bowel mucosa. It may be used as a tool in the detection of abnormalities of the small bowel in adults and children from 10 years of age and up. The Suspected Blood Indicator (SBI) feature is intended to mark frames of the video suspected of containing blood or red areas.
with PillCam™ ESO Capsule: The Given® Diagnostic System with the PillCam™ ESO Capsule is intended for the visualization of esophageal mucosa.
The Given® Diagnostic System is comprised of three subsystems: PillCam™ Capsule (ESO or SB), Data Recorder Set, and RAPID® Workstation. The PillCam™ Capsules are wireless, disposable capsules designed to glide smoothly through the GI tract. During its passage, the capsule transmits digital data that is captured by receiving antennas attached to the patient's body. The images are stored in the DataRecorder that is connected to the receiving antennas and is worn on a belt around the waist of the patient. When the test is over, the antennas and recorder are removed from the patient's body. The images from the recorder are downloaded to the RAPID® Workstation for processing and viewing by the physician. A new RAPID® software application, RAPID® 4, for the RAPID® Workstation is the subject of this submission.
The provided text describes the RAPID® 4 software for the Given® Diagnostic System. However, it does not include a detailed study proving the device meets specific acceptance criteria. The document primarily focuses on demonstrating substantial equivalence to previously cleared devices.
Here's an analysis of the requested information based on the provided text, highlighting what is present and what is missing:
1. Table of Acceptance Criteria and Reported Device Performance:
This information is not present in the document. The submission is for a software update (RAPID® 4) to an existing diagnostic system, and the clearance is based on substantial equivalence to previous versions, not on a new set of performance acceptance criteria and a study to meet them.
2. Sample Size Used for the Test Set and Data Provenance:
This information is not present. Since no new clinical performance study is detailed, there's no mention of a test set, its sample size, or data provenance. The document only references the existing system's intended use and design.
3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications of Those Experts:
This information is not present. Again, due to the nature of the submission (substantial equivalence for a software update), there is no mention of a new test set requiring expert ground truth establishment.
4. Adjudication Method for the Test Set:
This information is not present. As no test set is described, no adjudication method is mentioned.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, and the Effect Size:
This information is not present. The document does not describe any MRMC study or any comparison of human readers with and without AI assistance. The RAPID® 4 is a software for processing and viewing images, not explicitly an AI-assisted detection tool with a comparative effectiveness study detailed here.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Study Was Done:
This information is not present. There is no mention of a standalone algorithm performance study.
7. The Type of Ground Truth Used:
This information is not present. Without a specific performance study outlined, the type of ground truth used is not described.
8. The Sample Size for the Training Set:
This information is not present. The document focuses on the regulatory submission for a software update and does not detail the development or training of any underlying algorithms.
9. How the Ground Truth for the Training Set Was Established:
This information is not present. Similar to point 8, the document does not describe the establishment of ground truth for any training set.
Summary of what is available in the document:
- Device Name: RAPID® 4 (for Given® Diagnostic System)
- 510(k) Number: K052184
- Applicant: Given Imaging Ltd.
- Intended Use:
- With PillCam™ SB Capsule: Visualization of small bowel mucosa for detection of abnormalities in adults and children (10+). The Suspected Blood Indicator (SBI) feature marks frames with suspected blood or red areas.
- With PillCam™ ESO Capsule: Visualization of esophageal mucosa.
- Device Description: Comprised of PillCam™ Capsule (ESO or SB), Data Recorder Set, and RAPID® Workstation. The RAPID® 4 is a new software application for the RAPID® Workstation.
- Predicate Device: Given® Diagnostic System with previous versions of RAPID® software, and the Given® Diagnostic System with PillCam™ ESO Capsule.
- Basis for Clearance: Substantial equivalence to previously cleared devices, without raising new safety and/or efficacy issues. The system complies with "Class II Special Controls Guidance Document; Ingestible Telemetric Gastrointestinal Capsule Imaging System."
Conclusion:
The provided document is a 510(k) summary for a software update and emphasizes regulatory clearance based on substantial equivalence to existing devices. It does not present a detailed study outlining specific acceptance criteria and proving the device meets them via a new clinical performance study with associated sample sizes, expert ground truth, or comparative effectiveness studies. The assumption is that the previous versions of the software and system met these criteria, and RAPID® 4 maintains that performance.
§ 876.1300 Ingestible telemetric gastrointestinal capsule imaging system.
(a)
Identification. An ingestible telemetric gastrointestinal capsule imaging system is used for visualization of the small bowel mucosa as an adjunctive tool in the detection of abnormalities of the small bowel. The device captures images of the small bowel with a wireless camera contained in a capsule. This device includes an ingestible capsule (containing a light source, camera, transmitter, and battery), an antenna array, a receiving/recording unit, a data storage device, computer software to process the images, and accessories.(b)
Classification. Class II (special controls). The special control is FDA's guidance, “Class II Special Controls Guidance Document: Ingestible Telemetric Gastrointestinal Capsule Imaging Systems; Final Guidance for Industry and FDA.”